0.08
+0.008(+10.81%)
Currency In USD
| Previous Close | 0.07 |
| Open | 0.08 |
| Day High | 0.08 |
| Day Low | 0.08 |
| 52-Week High | 1.56 |
| 52-Week Low | 0.03 |
| Volume | 10,157 |
| Average Volume | 16,512 |
| Market Cap | 310,367 |
| PE | -0.02 |
| EPS | -3.74 |
| Moving Average 50 Days | 0.07 |
| Moving Average 200 Days | 0.35 |
| Change | 0.01 |
If you invested $1000 in IMAC Holdings, Inc. (BACK) since IPO date, it would be worth $0.74 as of September 29, 2025 at a share price of $0.082. Whereas If you bought $1000 worth of IMAC Holdings, Inc. (BACK) shares 5 years ago, it would be worth $3.41 as of September 29, 2025 at a share price of $0.082.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers
GlobeNewswire Inc.
Sep 10, 2025 7:04 PM GMT
The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study Golden, CO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, In
IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery
GlobeNewswire Inc.
Aug 07, 2025 8:05 PM GMT
Project will leverage Ignite Proteomics’ reverse-phase protein array (RPPA) platform to profile tumor-immune signaling in breast-cancer samples Golden, CO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc.
Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
GlobeNewswire Inc.
Feb 24, 2025 1:15 PM GMT
Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response t
Data not available